Novo Nordisk A/S

Copenhagen Stock Exchange NOVO-B.CO

Novo Nordisk A/S Price to Book Ratio (P/B) on January 14, 2025: 22.96

Novo Nordisk A/S Price to Book Ratio (P/B) is 22.96 on January 14, 2025, a -23.65% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Novo Nordisk A/S 52-week high Price to Book Ratio (P/B) is 41.57 on June 25, 2024, which is 81.05% above the current Price to Book Ratio (P/B).
Novo Nordisk A/S 52-week low Price to Book Ratio (P/B) is 22.96 on January 14, 2025, which is 0.00% below the current Price to Book Ratio (P/B).
Novo Nordisk A/S average Price to Book Ratio (P/B) for the last 52 weeks is 34.57.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Copenhagen Stock Exchange: NOVO-B.CO

Novo Nordisk A/S

CEO	Mr. Lars Fruergaard Jorgensen
IPO Date	Jan. 6, 2001
Location	Denmark
Headquarters	Novo Alle 1
Employees	71,880
Sector	Health Care
Industries Pharmaceuticals

Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Key trends

Past 5 years